PL3649109T3 - Pochodne etynylowe oraz ich otrzymywanie i zastosowanie terapeutyczne w leczeniu malarii - Google Patents

Pochodne etynylowe oraz ich otrzymywanie i zastosowanie terapeutyczne w leczeniu malarii

Info

Publication number
PL3649109T3
PL3649109T3 PL18734258T PL18734258T PL3649109T3 PL 3649109 T3 PL3649109 T3 PL 3649109T3 PL 18734258 T PL18734258 T PL 18734258T PL 18734258 T PL18734258 T PL 18734258T PL 3649109 T3 PL3649109 T3 PL 3649109T3
Authority
PL
Poland
Prior art keywords
malaria
preparation
treatment
therapeutic use
ethynyl compounds
Prior art date
Application number
PL18734258T
Other languages
English (en)
Inventor
Cécile PASCAL
Alain Pellet
Gilles Courtemanche
Simon Campbell
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL3649109T3 publication Critical patent/PL3649109T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18734258T 2017-07-04 2018-07-04 Pochodne etynylowe oraz ich otrzymywanie i zastosowanie terapeutyczne w leczeniu malarii PL3649109T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305866 2017-07-04
EP18734258.9A EP3649109B1 (en) 2017-07-04 2018-07-04 Ethynyl compounds, their preparation and their therapeutic use for the treatment of malaria
PCT/EP2018/068079 WO2019008027A1 (en) 2017-07-04 2018-07-04 ETHYNYL COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE IN THE TREATMENT OF MALARIA

Publications (1)

Publication Number Publication Date
PL3649109T3 true PL3649109T3 (pl) 2022-01-31

Family

ID=59350831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18734258T PL3649109T3 (pl) 2017-07-04 2018-07-04 Pochodne etynylowe oraz ich otrzymywanie i zastosowanie terapeutyczne w leczeniu malarii

Country Status (18)

Country Link
US (1) US11078160B2 (pl)
EP (1) EP3649109B1 (pl)
JP (1) JP7065898B2 (pl)
CN (1) CN110869350B (pl)
BR (1) BR112020000034B1 (pl)
CA (1) CA3069046A1 (pl)
CY (1) CY1124530T1 (pl)
DK (1) DK3649109T3 (pl)
ES (1) ES2894657T3 (pl)
HR (1) HRP20211806T1 (pl)
HU (1) HUE056766T2 (pl)
LT (1) LT3649109T (pl)
PL (1) PL3649109T3 (pl)
PT (1) PT3649109T (pl)
RS (1) RS62656B1 (pl)
SI (1) SI3649109T1 (pl)
SM (1) SMT202100683T1 (pl)
WO (1) WO2019008027A1 (pl)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577024B1 (de) * 1992-07-01 1996-10-16 Hoechst Aktiengesellschaft 3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
CA2444899C (en) * 2001-04-24 2011-06-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20110263901A1 (en) 2008-01-23 2011-10-27 Dhananjay Govind Sathe Process of Preparation of Proguanil
AU2009276744A1 (en) * 2008-07-28 2010-02-04 Polymedix, Inc. Anti-malarial compounds
WO2012149093A1 (en) 2011-04-26 2012-11-01 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF ARMY 2-guanidino-4-oxo-imidazoline derivatives as antimalarial agents, synthesis and methods of use thereof
EP2727911B1 (en) 2012-10-31 2016-12-21 Medizinische Hochschule Hannover Novel means and methods for treating malaria and other parasitic disorders

Also Published As

Publication number Publication date
DK3649109T3 (da) 2021-11-22
CN110869350B (zh) 2023-05-02
RS62656B1 (sr) 2021-12-31
HRP20211806T1 (hr) 2022-02-18
BR112020000034A2 (pt) 2020-09-29
HUE056766T2 (hu) 2022-03-28
US11078160B2 (en) 2021-08-03
JP7065898B2 (ja) 2022-05-12
SMT202100683T1 (it) 2022-01-10
CA3069046A1 (en) 2019-01-10
EP3649109B1 (en) 2021-09-01
JP2020525496A (ja) 2020-08-27
CY1124530T1 (el) 2022-07-22
SI3649109T1 (sl) 2021-11-30
LT3649109T (lt) 2021-09-27
ES2894657T3 (es) 2022-02-15
EP3649109A1 (en) 2020-05-13
CN110869350A (zh) 2020-03-06
WO2019008027A1 (en) 2019-01-10
PT3649109T (pt) 2021-09-10
US20200281909A1 (en) 2020-09-10
BR112020000034B1 (pt) 2023-10-10

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
IL260383B (en) Low dose medication
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
IL264156A (en) Compounds, preparations and methods for treating the disease
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
GB201715194D0 (en) Compounds and their therapeutic use
GB201617064D0 (en) Compounds and their therapeutic use
IL270460B1 (en) New compounds and their medicinal uses
SI3353164T1 (sl) Bi-heteroaril substituiran 1,4-benzodiazepini in njihove uporabe za zdravljenje raka
PL3119752T3 (pl) Związki 3,4-diamino-6-chloropirazyno-2-karbokysamidowe do leczenia chorób mediowanych przez ENAC
LT3649109T (lt) Etinilo junginiai, jų gamyba ir jų terapinis panaudojimas maliarijos gydymui
GB201819430D0 (en) Therapeutic compounds, nanoparticles and uses thereof
GB201705684D0 (en) Novel compounds and therapeutic uses thereof
IL259712B (en) Stable dosage form of conjugated etidronate-cytrabine, and use thereof
AU2017902160A0 (en) New Therapeutic Treatment Combination
AU2016902139A0 (en) New Therapeutic Treatment Combination
IL251930A0 (en) Anylhydroxy derivatives, their preparation and medical uses
GB201707076D0 (en) Novel compounds and therapeutic uses thereof
GB201705682D0 (en) Novel compounds and therapeutic uses thereof
GB201705683D0 (en) Novel compounds and therapeutic uses thereof
GB201705681D0 (en) Novel compounds and therapeutic uses thereof
GB201705685D0 (en) Novel compounds and therapeutic uses thereof
GB201705678D0 (en) Novel compounds and therapeutic uses thereof